Joshua Fairbank

Fairbank has spent over two decades on both sides of the table; as an investor and as an entrepreneur. He is the President of Orchard Capital Management where he sits on the investment committees for the small cap value and the alternative asset strategies. In 2004 he co-founded and led the investment team at Orchard Ventures, a biotech VC fund.

In addition to Orchard Capital and Orchard Ventures he is the co-founder of several companies. At Akebia (NASDAQ:AKBA) he wrote the original business plan, negotiated the spin-out from Procter Gamble, and served as a founding director. Akebia is developing an anemia drug that mimics the body’s physiological response to high altitude, it has been tested in over ten thousand patients, has been approved internationally, and is completing its US application. Early on at Akebia they spun off the blindness-related assets into a new company, Aerpio Pharmaceuticals (NASDAQ: ARPO), that they also took public.

He runs Nymirum as its co-founder and Executive Chairman. Nymirum is a computational genetics firm that harnesses AI and big data to work on multiple unsolved diseases including cancers, neurodegenerative diseases, and infectious diseases. Joshua has negotiated partnerships with several leading global pharmaceutical companies and secured significant non-dilutive funding. He is a joint inventor on one of Nymirum's biophysics patents.